ACS 2018 Cancer Facts & Figures Highlights the Urgent Need for Early Detection Tools and Effective Treatments in Pancreatic Cancer
The American Cancer Society (ACS) recently released updated Cancer Facts & Figures report, providing a snapshot of American cancer statistics and predictions across all cancer sites. In the US, the ACS estimates there will be 56,770 people diagnosed with pancreatic cancer and 45,750 deaths from pancreatic cancer this year.
In general, the cancer incidence rate in men has been declining by ~2% per year over the past decade, and has remained stable in women during the same time period, but the incidence of pancreatic cancer is rising in both sexes. Unfortunately, pancreatic cancer maintains its position as the cancer with lowest survival rate of any cancer site, with a 5-year survival rate of just 9%.
“In contrast to the steady increase in survival for most cancer types, advances have been slow for lung and pancreatic cancers, partly because greater than one‐half of cases are diagnosed at a distant stage”, the authors state. (p.9) They went on to say that cancer mortality has declined for lung, breast, prostate, and colorectum cancers as a result of “steady reductions in smoking and advances in early detection and treatment.” (p.10)
“While not surprising, these statistics are a sobering reminder why tools for the early detection of pancreatic cancer, such as Immunovia’s IMMray™ PanCan-d, along with the development of more effective treatments are so important”, says Mats Grahn, CEO, Immunovia.
Ref: Siegel RL, Miller KD, Jemal A. CA Cancer J Clin. 2019;0:1-28.